Zur Kurzanzeige

dc.contributor.authorMarín, Miguel
dc.contributor.authorSánchez-Montejo, Javier
dc.contributor.authorRamos, Sergio
dc.contributor.authorLópez Abán, Julio 
dc.contributor.authorPeláez Lamamie de C. Arroyo, Rafael 
dc.contributor.authorMuro Álvarez, Antonio 
dc.date.accessioned2025-01-31T08:29:17Z
dc.date.available2025-01-31T08:29:17Z
dc.date.issued2024-09-19
dc.identifier.citationMarín M, Sánchez-Montejo J, Ramos S, Muro A, López-Abán J, Peláez R. Deciphering Chemical Rules for Drug Penetration into Strongyloides. Pharmaceutics. 2024 Sep 19;16(9):1224. doi: 10.3390/pharmaceutics16091224es_ES
dc.identifier.issn1999-4923
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10366/163236
dc.description.abstractBackground: Strongyloidiasis, a parasitic infection, presents a significant public health challenge in tropical regions due to the limited repertoire of effective treatments. The screening of chemical libraries against the therapeutically relevant third-stage larvae (L3) of the model parasite Strongyloides venezuelensis yielded meager success rates. This situation is reminiscent of Gram-negative bacteria, where drug entry is a limiting factor. Methods: Here, we set out to determine whether similar barriers are in place and establish whether structural and property requirements exist for anti-strongyloides drug discovery. We focused on dyes as their uptake and effects on viability can be independently assessed in the multicellular parasite, thus providing a means to study the possibility of similar entry rules. We tested different dyes in in vitro assays on L3s. Results: We found that staining was necessary to reduce parasite viability, with some dyes achieving anti-strongyloides effects at concentrations similar to those of the reference drug, ivermectin (IV). Some dyes also showed activity against female adults at concentrations well below that of ivermectin. Unfortunately, the most potent dye, Methylene Blue, was unable to prevent the infection in a preliminary in vivo mouse model assay, presumably due to fast dye clearance. Structural analysis showed that positive charges facilitated the access of the compounds to the L3 tissue, thus providing a structural tool for the introduction of activity. For female adults, low globularity is additionally required. As a proof of concept, we added a positive charge to an inactive compound of one of our chemical libraries and re-determined the activity. Conclusions: These findings allow us to establish structural rules for parasite entry that could be of interest for future drug screening or drug development campaigns. These rules might also be applicable to other related parasites.es_ES
dc.description.sponsorshipGrant PID2021-127471OB-I00, funded by MCIN/AEI/10.13039/ 501100011033, Junta de Castilla y León (SA0116P20), and “ERDF A way of making Europe” by the “European Union”. M.M. thanks Junta de Castilla y León for a predoctoral fellowship 2020 cofounded by the EU Social Funds (ORDEN EDU/601/2020) and an EMBO Scientific Exchange Grant (SEG number: 10384). S.R. acknowledges a predoctoral fellowship from the Universidad de Salamanca Programa III 2018, cofounded by Banco de Santander. J.S.M. acknowledges the predoctoral fellowship program of Junta de Castilla y León, cofunded by “Fondo Social Europeo” (Orden EDU875/2021).es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectStrongyloides venezuelensis
dc.subjectdyes
dc.subjectnematocidal activity
dc.subjectstructure–activity relationships
dc.subjectentry rules
dc.titleDeciphering Chemical Rules for Drug Penetration into Strongyloides.es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.3390/pharmaceutics16091224es_ES
dc.subject.unesco3205.05 Enfermedades Infecciosas
dc.identifier.doi10.3390/pharmaceutics16091224
dc.relation.projectIDPID2021-127471OB-I00,es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.pmid39339260
dc.identifier.essn1999-4923
dc.journal.titlePharmaceuticses_ES
dc.volume.number16es_ES
dc.issue.number9es_ES
dc.page.initial1224es_ES
dc.page.final1224es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: Attribution-NonCommercial-NoDerivatives 4.0 Internacional